NMN supplement effects: what is established and what applies in the EU

What to expect in this article

1. What NMN is and what NAD+ has to do with it
2. What is legally applicable in Germany and the EU
3. The 2026 EFSA opinion and what follows from it
4. Why there is no authorized health claim for NMN
5. The NAD+ narrative in three parts, examined individually
6. How a substance becomes legally marketable in the EU in the first place
7. Why the mouse data cannot be extrapolated to humans
8. What was actually measured in human studies
9. Three NAD+ precursors and their very different legal statuses
10. What a DNA test can and cannot contribute to this question
11. How to recognize an impermissible advertising claim
12. Limitations: what this article does not answer
13. What matters about this topic
14. Frequently asked questions
15. Sources

What NMN is and what NAD+ has to do with it

NMN is short for nicotinamide mononucleotide, a small molecule involved in the metabolism of vitamin B3. It is not an invention of the dietary supplement industry, but an intermediate known for decades that occurs in every human cell and is also present in trace amounts in foods.

The molecule attracted interest because of its role as a precursor. A precursor is a substance from which the body produces another substance. In the case of NMN, that other substance is NAD+, short for nicotinamide adenine dinucleotide.

What a coenzyme is and why NAD+ is mentioned so often

A coenzyme is a helper molecule without which an enzyme cannot do its job. NAD+ is such a helper, and a particularly versatile one: It transfers electrons in the respiratory chain and also serves as a building block for a range of enzymes involved in repair and regulatory processes.

This dual role explains the attention it receives. A molecule that occurs in both energy metabolism and cell regulation can be linked to almost any health topic. That, however, is also where the narrative is weak: A substance involved everywhere is rarely the single lever on which something depends.

In our metabolism, NAD+ functions more like a checkout card in a workshop than like a tool. It is constantly issued, used, returned, and issued again. Whether having more cards in circulation leads to more things being built depends on whether the cards were actually the bottleneck.

Where NMN fits into vitamin B3 metabolism

The body has several ways of producing NAD+. It can build it from the amino acid tryptophan, obtain it from nicotinic acid and nicotinamide, and recover it through so-called salvage pathways from material that has already been used. NMN lies on one of these pathways, immediately before the final step.

This proximity to the end product is the industry’s main argument: a short route and few conversion steps. But it is not evidence of a benefit; it is a description of biochemistry. Several levels of evidence lie between a plausible reaction pathway and a demonstrated effect in humans, and this article examines them one by one.

What legally applies in Germany and the EU

Before discussing effects, there is a preliminary question: May the substance legally be sold here as a food at all? For NMN, the answer as of August 28, 2026, is no, and this answer is older and more robust than any body of study results.

The decisive factor is the European regulation on novel foods. The Federal Office of Consumer Protection and Food Safety explains the term as follows: A novel food is anything that was not used to a significant extent for human consumption in the European Union before May 15, 1997. According to the BVL, such foods must undergo a safety assessment before they may be placed on the market.

In its information on NAD and NMN, the consumer advice center first discusses NAD+ itself and then compares it with NMN. The following quotation, with the word “by contrast,” refers to this comparison.

Why the substance is nevertheless being offered

The fact that a substance can be purchased online says nothing about whether it is legally marketable in the EU. A significant share of the products offered comes from countries with different legislation and reaches buyers via direct shipping. Food authorities generally intervene only when they come across a specific case.

For you as a reader, this has a practical consequence that has little to do with biochemistry. For a product without European authorization, there are no officially verified details regarding purity and content. What is stated on the packaging is then merely a manufacturer’s claim.

The 2026 EFSA opinion and what follows from it

In 2026, there has been some movement on this issue, and this development is currently often misrepresented. That is why it is discussed here in detail.

The European Food Safety Authority’s Panel on Nutrition, Novel Foods and Food Allergens adopted an opinion on beta-nicotinamide mononucleotide. It was adopted on March 4, 2026, and published on May 11, 2026, in the EFSA Journal. The substance was assessed as an ingredient in food supplements and as a source of nicotinamide, a form of the vitamin niacin.

The Panel concluded that the substance is safe for the adult population under the proposed conditions of use, except for pregnant and breastfeeding women, and that it is a bioavailable source of nicotinamide. The maximum amount proposed and assessed was 300 milligrams per day. This figure is a basis for assessing an authorization application, not a recommendation for individuals.

Three things this opinion expressly does not say

First, it says nothing about efficacy. The opinion itself states that the assessment relates exclusively to the risks that may be associated with consumption under the proposed conditions of use, and that it is not an assessment of efficacy with regard to any claimed benefit. The distinction between safety and efficacy could hardly be expressed more clearly.

Second, an EFSA opinion is not an authorization. EFSA conducts the assessment, while the European Commission, together with the Member States, makes the decision. A substance becomes legally marketable only once it has been added to the Union list of authorized novel foods. NMN was not listed there when the list was checked on August 28, 2026.

Third, the application does not concern the longevity narrative but vitamin supply. NMN was assessed as a source of nicotinamide. The framework in which the substance may one day be permitted is therefore nutrient supply with niacin, not slowing aging.

Why there is no permitted claim about NMN’s effects

Even if a substance is legally marketable, it cannot be advertised freely. Health claims about foods are specifically regulated in the EU and are permissible only if they have first been assessed and included on a list. For niacin, this list includes several claims, such as contributing to normal energy-yielding metabolism, as set out in Regulation (EU) No 432/2012.

For NMN, it does not lead to anything. In its information dated January 16, 2026, the consumer advice center states that there are currently no authorized health claims whatsoever, and it likewise notes that there is no scientific evidence that NMN as a dietary supplement makes people younger, healthier, and more vital, or extends life.

This leads to a hard consequence for any text on this subject. There is no softened wording that would be permissible. A sentence such as “may support energy metabolism” is not a cautious version of a claim about effects; it is a claim about effects. The subjunctive does not change the legal classification.

The scale of the evidence

Sources: European Commission, Union list of novel foods and Regulation (EU) No 432/2012, accessed 2026 · Igarashi and colleagues, npj Aging, 2022

The NAD+ narrative in three links, examined individually

Almost every text about NMN tells the same chain of events. It goes like this: NMN raises NAD+ levels, NAD+ levels decline with age, therefore NMN counteracts aging. The chain sounds convincing because each link seems plausible on its own. It is hardly ever examined, however, because its three links are supported by evidence to very different degrees.

First link: Does NMN raise NAD+ levels?

For the blood marker, the answer is yes. In a double-blind, placebo-controlled study of healthy older men, blood concentrations of NAD+ and its breakdown products increased measurably. This was described by Igarashi and colleagues in npj Aging (2022), with 250 milligrams daily for twelve weeks and twenty participants evaluated.

The first link therefore holds. But it is narrower than it is usually quoted: Measurements were taken in blood. This does not answer whether, or to what extent, levels in muscle, liver, adipose tissue, or the brain follow the same pattern. A review by Vinten and colleagues in Nature Metabolism (2025) explicitly notes that published data on NAD+ dynamics in human tissues remain sparse.

Second link: Do NAD+ levels decline with age?

This is where the chain breaks for the first time. A review by Peluso and colleagues in Nutrients (2022) compiled the available measurements across several species and concluded that the evidence for a general age-related decline is very limited and mostly restricted to a single tissue or cell type. In humans, the course of NAD+ levels over the course of aging has so far been poorly characterized.

The review by Vinten and colleagues (2025) puts it similarly cautiously: An age-related decline in NAD+ levels in humans has been consistently observed in only a limited number of studies. A statement presented as self-evident is therefore an open research question.

Third link: Does this result in rejuvenation?

The third link does not hold. It would not hold even if the first two did, because an elevated concentration does not imply an outcome unless the outcome itself has been measured. Vinten and colleagues summarize the clinical situation in Nature Metabolism (2025) by stating that human studies have so far shown limited efficacy.

This exact gap between marker and outcome is where honest classification and advertising diverge. Advertising names the first link and infers the third. The evidence for that is missing.

How a substance becomes marketable in the EU in the first place

Anyone who wants to understand why a positive safety assessment and an authorized product are two different things must know the path a novel food takes through the EU. It consists of four stages, and their order is mandatory.

The procedure applied to NMN

The fourth stage is most often overlooked. Even a substance that is someday included on the Union list may therefore not be advertised with a claimed effect for a long time. This has applied to the related precursor nicotinamide riboside chloride since 2020: approved as an ingredient, without its own authorized health claim.

Why mouse data cannot be transferred to humans

NMN's reputation comes predominantly from animal studies. Over the years, mouse models have produced findings on metabolism, endurance, and vascular function, and these findings are what appear as proof in advertising copy, usually without naming the animal species.

The review by Vinten and colleagues in Nature Metabolism (2025) states the problem directly: Data from rodents cannot be transferred without further ado. This is not a formality but has tangible reasons.

Four reasons that stand between mouse and human

The first reason is lifespan. A laboratory mouse lives for two to three years. An intervention that works for months in a mouse corresponds to a period in humans that no study has yet covered.

The second reason is genetic uniformity. Laboratory strains are largely identical and live under controlled conditions. People differ in genetics, diet, physical activity, sleep, and pre-existing conditions, and any of these differences can mask a small effect.

The third reason is the dose. In animal studies, amounts are given per kilogram of body weight and cannot be converted linearly to humans because metabolic rate and excretion differ between species.

The fourth reason is the study model. Many animal studies use deliberately induced deficiency or disease states. An effect that offsets an artificially induced deficiency says little about a healthy person without that deficiency.

What was actually measured in human studies

Human studies are available, but they are small and short, and their results are inconsistent. The most frequently cited is the previously mentioned study by Igarashi and colleagues in npj Aging (2022). It serves well as an example because it shows both what changed and what did not.

Healthy older men were studied. Twenty participants were evaluated, ten per group. The study administered 250 milligrams daily for twelve weeks. These details describe a study design and are explicitly not instructions for taking it.

What changed

The concentration of NAD+ and its breakdown products in the blood increased. The analysis also showed differences in walking speed and left-hand grip strength. The substance was well tolerated in this study, and no serious adverse events were reported.

What did not change

The list of endpoints showing no difference is longer than the list showing one. No effect is reported on skeletal muscle mass, no significant change in body composition, no effect on liver or abdominal fat, and no effect on insulin sensitivity or glucose metabolism.

That is exactly what an honest body of evidence looks like. One marker changes, individual functional measures change along with it in a very small group, while most of the measured variables remain unchanged. Anyone who derives a longevity promise from this is not reading the paper, but using its title.

A second point also needs to be considered with small groups. With twenty people evaluated and a range of endpoints considered simultaneously, a single striking result can easily occur by chance. Such a finding becomes robust only when replicated in larger, independent studies.

Three NAD+ precursors and their very different legal statuses

NMN is not the only precursor in the same metabolic pathway. A comparison of the three best-known precursors makes it clear that their legal status does not depend on their biochemical similarity, but on whether a procedure has been completed.

The middle column is the most revealing. Nicotinamide riboside chloride has gone through the procedure and is authorized, yet there is still no separate authorized health claim behind it. Authorization as an ingredient and permission to advertise are two separate things, and both are absent for NMN.

What a DNA test can and cannot contribute to this question

At this point, many texts transition to the product. Here, that transition should be stated openly because it does not hold in this case: A DNA test does not measure NAD+ and says nothing about the effects of a dietary supplement.

A saliva test reads predetermined positions in the DNA sequence. It therefore describes predispositions that do not change over the course of a person’s life. NAD+, by contrast, is a metabolic state that shifts over the course of hours and would have to be determined from a blood or tissue sample. The two belong to different categories, and no genotype can be translated into an NAD+ value.

What a genetic report can do lies on a different level. It describes predispositions related to nutrition, exercise, and metabolism, thereby providing a starting point for decisions that do not depend on a single molecule. That is less than longevity advertising promises, and it can be verified. The test by mybody®x (MYBODY Lab GmbH) is therefore explicitly not presented here as an answer to the NMN question, but as what it is.

DNA test from a saliva sample

Longevity | ALL IN ONE DNA test

According to the product page, it evaluates more than 170 genetic variants and provides 54 reports on nutrition, exercise, metabolism, and skincare. What the test does not do regarding this article’s topic: It does not measure NAD+, assess NMN status, say anything about the effects of a dietary supplement, or make any statement about life expectancy. NMN and NAD+ do not appear on the product page. It describes predispositions, does not diagnose, and does not predict the course of anything.

Price €369.00 As of 27 August 2026; subject to change

Sample type Saliva sample

Processing time Kit shipping: 1–3 business days
Laboratory analysis 15–25 business days after receipt of the sample

Laboratory laboratory-guided analysis
Product page statement, accessed 27 August 2026

To the Longevity DNA Test

This distinction also applies in relation to our article What Is Epigenetics. That article addresses how gene activity is regulated and what a saliva test reads from it. Here, the focus is a single substance, its legal status, and the state of the evidence. Anyone who wants to know what genetic analyses actually measure will find that article more helpful.

How to recognize an impermissible advertising claim

The most useful skill on this topic is not specialist knowledge about NAD+, but an eye for how a claim is constructed. Four questions are enough, and they work for any other longevity claim too.

The fourth step is the quickest, which is why it is worth starting with it. It requires no specialist knowledge and disposes of most claims within a few seconds.

It is also striking which words regularly appear in such texts: rejuvenation, cellular age, molecular reset, fountain of youth. None of these words is a measurement. They replace stating what was actually examined with an image that everyone understands and no one can verify.

Limitations: what this article does not answer

This text provides context and does not recommend anything. It says neither that NMN is useless nor that it is useful. It says that neither has currently been proven and that the substance is not marketable here. These are two different statements, and the second is the more robust one.

The legal situation may change. A safety assessment has been available since May 2026, and a decision by the European Commission is pending. If it decides in favor of authorization, this will change the product’s marketability, but not the question of its effects. A claim about effects would require a separate procedure and data that are not available today.

There remains a gap in the evidence that this article cannot close. Large, long-term studies by independent groups involving people and using endpoints that matter in everyday life are lacking. Until they exist, any statement about the benefits remains an extrapolation from small groups and short periods.

And regarding mybody®x products, the limitation from the tenth chapter remains unchanged. None of the tests in the range measures NAD+, none tests the effect of a supplement, and none answers the question that brought you to this page. Anyone who wants an answer must wait for research results that do not yet exist.

What matters about this topic

At the beginning was the question of NMN’s effects. Based on the current state of knowledge, it cannot be answered, and that is itself an answer: A substance for which there is not a single authorized health claim in the EU and which is not on the Union list has no effect that could legally be advertised.

What remains from this article is less a statement about NMN than a tool. The chain of marker, aging, and rejuvenation appears again with every new longevity substance, usually with only the molecule’s name changed. Once you have broken it down into its components, you recognize it the next time by its structure before you have even read the name.

The specific next step is therefore not a purchase, but a habit: the next time you encounter a claim about an effect, first check whether an authorized health claim exists for it. It takes a minute and answers more questions than reading any study.

Frequently asked questions

Sources

1. Consumer Advice Centre: NAD and NMN in food supplements? (as of January 16, 2026) – verbraucherzentrale.de
2. German Federal Office of Consumer Protection and Food Safety: Novel Foods (accessed 2026) – bvl.bund.de
3. EFSA Panel on Nutrition, Novel Foods and Food Allergens: Safety of beta-nicotinamide mononucleotide (β-NMN) … EFSA Journal, adopted on March 4, 2026, published on May 11, 2026 – efsa.onlinelibrary.wiley.com
4. European Commission: Union list of authorized novel foods, Commission Implementing Regulation (EU) 2017/2470 (accessed 2026) – food.ec.europa.eu

The statements on the novel-food status of NMN, the absence of authorized health claims, and the lack of evidence for fountain-of-youth claims are based on [1]. The definition of a novel food, the cutoff date of May 15, 1997, the requirement for authorization before placing a product on the market, and the role of the Union list are taken from [2]. The date of adoption, March 4, 2026, the publication date, May 11, 2026, the assessed maximum amount of 300 milligrams per day, the classification as a source of nicotinamide, and the explicit exclusion of an efficacy assessment are taken from [3]. The fact that NMN is not included in the Union list was checked against [4]. The study details concerning 250 milligrams daily for twelve weeks, twenty participants evaluated, and the changed and unchanged endpoints come from a paper by Igarashi and colleagues in npj Aging (2022); the statements on the human evidence base come from reviews by Peluso and colleagues in Nutrients (2022) and Vinten and colleagues in Nature Metabolism (2025); the authorization of nicotinamide riboside chloride comes from Commission Implementing Regulation (EU) 2020/16 of January 10, 2020. These four references are attributed in the main text by authorship or source and year and therefore do not appear in the list. Information on price, genetic variations, number of reports, sample type, and laboratory comes from the mybody®x product page, accessed on August 27, 2026; processing times follow the central specification for DNA tests. All sources were accessed and checked on August 28, 2026.

mybody®x Editorial & Specialist Team

Food law Nutritional science Nutrigenetics Laboratory diagnostics

This article was produced by the mybody®x editorial and specialist team. The team combines nutrigenetics, laboratory diagnostics, and nutritional science. The people who contribute to it are listed on the authors’ page.

Published on 08/06/2026 · Last updated on 08/27/2026

The content is for general information only and does not replace medical advice, diagnosis, or treatment. Our products are not intended to diagnose, treat, cure, or prevent diseases. This article is not a recommendation to take a dietary supplement.